TABLE I.

Dose tolerance and discontinuations related to safety in studies of sunitinib

Study			Patients (n)	Dose (%)			Discontinuations because of adverse events (%)
Reference	Phase	Tumour type		Intensity	Reductions	Interruptions
Continuous daily dosing (37.5 mg daily) in various cancers
Escudier et al., 200926	Phase ii	rcc	107	93	43	65	15
George et al., 200921	Phase ii	gist	60	nr	23	77	7
Novello et al., 200928	Phase ii	nsclc	47	nr	29.8	36.2	25.5
Raymond et al., 201127	Phase iii	Pancreatic	86 Sunitinib	91.3	31	30	17
		net	85 Placebo	100.6	11	12	8
Schedule 4/2a in pancreatic net
Kulke et al., 200832	Phase ii		107 (41 carcinoid, 66 pancreatic net)	nr	47.7	62.6	10.2

^aFour consecutive weeks of every six weeks.

gist = gastrointestinal stromal tumour; nr = not reported; rcc = renal cell cancer; nsclc = non-small-cell lung cancer; net = neuroendocrine tumour.